Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb reported Q2 revenue of $12.9B, up 6% year over year, EPS of $1.62, up 153%, and more than $3B of free cash flow, supporting the bullish case despite looming Eliquis and Opdivo patent expirations. Growth drugs generated nearly 60% of revenue and grew 15% in Q2, while BMY trades below 10x forward earnings and offers a 3.95% dividend yield backed by a roughly 44% FCF payout ratio and a $5B buyback authorization. Reports of merger discussions with AstraZeneca valuing BMY at $400B create additional upside potential, although such a transaction would face significant regulatory scrutiny.

Analysis

BMY's discount is not a simple valuation anomaly; it prices a credibility gap around replacing post-LOE cash flows rather than an imminent dividend or liquidity problem. The investable inflection is whether the newer portfolio can sustain mid-teens growth while legacy erosion accelerates: that determines whether consensus must re-underwrite 2027-29 earnings rather than merely lift the near-term multiple. A durable rerating likely requires two consecutive quarters of raised revenue guidance or clear evidence that new-product growth is offsetting the absolute-dollar decline in Eliquis and Opdivo.

The reported AZN transaction framing should not be capitalized into fair value without independently sourced confirmation; the implied scale appears economically and politically implausible, and a broad oncology/cardiovascular overlap would invite a long regulatory timetable. Rumor-driven strength would more likely create an opportunity to sell upside volatility than to chase common stock. AZN is the less attractive expression of any speculation because an all-cash or heavily financed transaction could pressure its leverage, credit spread, and buyback capacity before any synergies are realizable.

Near term, BMY's capital return supports downside better than high-multiple pharma peers, but patent-cliff narratives can remain persistent for 6-18 months absent pipeline validation. The contrarian opportunity is that the market may be assigning too little value to successful late-stage execution, but the article's earnings framing does not establish normalized EPS quality; investors should separate operating growth from comparison effects, deal amortization, and one-off items. Failure of a pivotal pipeline program, an accelerated competitor launch, or a cut to 2027 revenue expectations would invalidate the rerating thesis quickly.

Key Decisions for Investors

• Initiate a modest 6-12 month long BMY / short ABBV pair only on confirmation that BMY's new-product revenue growth remains at least 12-15% and management maintains medium-term revenue guidance. Target 10-15% relative upside from partial multiple convergence; exit if BMY cuts 2027 sales outlook or if the growth portfolio falls below 10% year-over-year for two quarters.
• Do not underwrite an AZN acquisition premium. If unverified deal headlines push BMY materially above fundamental value, consider selling 3-6 month out-of-the-money BMY call spreads rather than shorting stock outright; cap event risk through defined-risk structures because a credible bid could gap shares higher.
• For income-oriented exposure, own BMY equity rather than reaching for unsecured credit: the equity has pipeline optionality while cash generation presently cushions capital returns. Reassess after each earnings release for net-debt reduction, buyback execution, and whether dividend growth remains covered by normalized free cash flow.
• Set an event watch on pivotal data for milvexian and other late-stage assets, plus quarterly disclosure of absolute legacy-product sales declines. Positive clinical/regulatory outcomes are the 6-18 month catalyst for a rerating; negative data would favor reducing BMY and potentially rotating to MRK or JNJ, which have less dependence on a single replacement narrative.